Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Before the advent of tyrosine kinase inhibitors (TKIs), Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) was associated with dismal survival without allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent evidence has demonstrated that the combination of TKI and chemotherapy can result in a high rate of complete remission, thereby enabling more patients to proceed to allo-HSCT. However, with more studies reporting non-inferior outcomes with TKI and chemotherapy combination without allo-HSCT, the need for allo-HSCT in Ph+ ALL has become less certain. This review summarizes evidence that will address the relevance of allo-HSCT in Ph+ ALL.

Original languageEnglish (US)
JournalBest Practice and Research: Clinical Haematology
DOIs
StateAccepted/In press - Jan 1 2018

Keywords

  • Acute lymphoblastic leukemia
  • ALL
  • allo-HSCT
  • Allogeneic hematopoietic stem cell transplantation
  • Ph+
  • Philadelphia chromosome positive
  • TKI
  • Tyrosine kinase inhibitor

ASJC Scopus subject areas

  • Oncology
  • Clinical Biochemistry

Fingerprint Dive into the research topics of 'Allogeneic transplantation for patients with Philadelphia chromosome positive acute lymphoblastic leukemia: Is it imperative in the tyrosine kinase inhibitor era?'. Together they form a unique fingerprint.

  • Cite this